PanGen Biotech Price To Sales vs. Return On Asset

222110 Stock  KRW 5,720  260.00  4.76%   
Considering the key profitability indicators obtained from PanGen Biotech's historical financial statements, PanGen Biotech may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess PanGen Biotech's ability to earn profits and add value for shareholders.
For PanGen Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of PanGen Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well PanGen Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between PanGen Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of PanGen Biotech over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between PanGen Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PanGen Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PanGen Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

PanGen Biotech Return On Asset vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining PanGen Biotech's current stock value. Our valuation model uses many indicators to compare PanGen Biotech value to that of its competitors to determine the firm's financial worth.
PanGen Biotech is number one stock in price to sales category among its peers. It is rated second in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value PanGen Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for PanGen Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

PanGen Return On Asset vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

PanGen Biotech

P/S

 = 

MV Per Share

Revenue Per Share

 = 
13.35 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

PanGen Biotech

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.079
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

PanGen Return On Asset Comparison

PanGen Biotech is currently under evaluation in return on asset category among its peers.

PanGen Biotech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in PanGen Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, PanGen Biotech will eventually generate negative long term returns. The profitability progress is the general direction of PanGen Biotech's change in net profit over the period of time. It can combine multiple indicators of PanGen Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
PanGen Biotech Inc. operates as a specialized biologics company in South Korea. The company was founded in 1999 and is based in Suwon, South Korea. PanGen is traded on Korean Securities Dealers Automated Quotations in South Korea.

PanGen Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on PanGen Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of PanGen Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the PanGen Biotech's important profitability drivers and their relationship over time.

Use PanGen Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PanGen Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PanGen Biotech will appreciate offsetting losses from the drop in the long position's value.

PanGen Biotech Pair Trading

PanGen Biotech Pair Trading Analysis

The ability to find closely correlated positions to PanGen Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PanGen Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PanGen Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PanGen Biotech to buy it.
The correlation of PanGen Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PanGen Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PanGen Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PanGen Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your PanGen Biotech position

In addition to having PanGen Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Driverless Cars Thematic Idea Now

Driverless Cars
Driverless Cars Theme
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in PanGen Stock

To fully project PanGen Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of PanGen Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include PanGen Biotech's income statement, its balance sheet, and the statement of cash flows.
Potential PanGen Biotech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although PanGen Biotech investors may work on each financial statement separately, they are all related. The changes in PanGen Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on PanGen Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.